Massmutual Trust Co. FSB ADV purchased a new position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 4,795 shares of the biopharmaceutical company’s stock, valued at approximately $392,000.
A number of other hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Agios Pharmaceuticals by 14.0% during the 1st quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock worth $262,192,000 after buying an additional 393,336 shares during the period. Lord Abbett & CO. LLC raised its stake in Agios Pharmaceuticals by 175.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock worth $85,407,000 after buying an additional 665,684 shares during the period. Alkeon Capital Management LLC raised its stake in Agios Pharmaceuticals by 30.7% during the 1st quarter. Alkeon Capital Management LLC now owns 668,789 shares of the biopharmaceutical company’s stock worth $54,694,000 after buying an additional 157,170 shares during the period. Baillie Gifford & Co. acquired a new position in Agios Pharmaceuticals during the 1st quarter worth approximately $47,607,000. Finally, Point72 Asset Management L.P. raised its stake in Agios Pharmaceuticals by 343.8% during the 1st quarter. Point72 Asset Management L.P. now owns 406,090 shares of the biopharmaceutical company’s stock worth $33,210,000 after buying an additional 314,590 shares during the period. 94.22% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms recently weighed in on AGIO. BidaskClub downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 4th. Citigroup began coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $117.00 price target on the stock. Credit Suisse Group set a $95.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Finally, SunTrust Banks set a $115.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $95.55.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.03). The company had revenue of $8.80 million during the quarter, compared to analysts’ expectations of $11.93 million. Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The business’s revenue for the quarter was down 16.2% compared to the same quarter last year. During the same period last year, the company earned ($1.56) earnings per share. equities research analysts predict that Agios Pharmaceuticals Inc will post -6.24 EPS for the current year.
In other news, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the transaction, the insider now directly owns 2,881 shares of the company’s stock, valued at $245,173.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO David P. Schenkein sold 13,000 shares of the company’s stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $95.35, for a total value of $1,239,550.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 173,227 shares of company stock valued at $15,393,571. 3.02% of the stock is currently owned by corporate insiders.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.